This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Proteomics Core provides state-of-the art instrumentation and support for the research efforts of the members of this COBRE Cancer Center, other COBRE Centers located in Rhode Island and greater academic community. Our fee-based services include mass spectrometric analyses such as LC/MS/MS and SELDI-TOF mass spectrometry, electrophoretic analyses, including SDS-PAGE, isoelectric focusing, 2-D electrophoresis, immunoblot, and image analysis by use of the VersaDoc Imaging System, and protein and peptide chromatography and peptide synthesis. We also offer expertise in protein purification and characterization, and small-scale down stream processing. Our facility is located in the Coro Center at RI Hospital. In this year, a total of 23 research groups have made use of our services and facilities. Seven investigators currently use instruments in our laboratory, mainly the mass spectrometer, Ciphergen SELDI-TOF chromatographic systems for isolation, identification and characterization of their samples. Both of our mass spectrometers, a QStar XL LC/MS/MS system from ABI and SELDI-TOF from Ciphergen are in routine use. The SELDI-TOF system is also available for non-proteomics core investigators. We have also newly trained four young investigators from other COBRE laboratories to use this instrument.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR017695-05
Application #
7381871
Study Section
Special Emphasis Panel (ZRR1-RI-A (02))
Project Start
2006-07-01
Project End
2007-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
5
Fiscal Year
2006
Total Cost
$525,698
Indirect Cost
Name
Rhode Island Hospital
Department
Type
DUNS #
075710996
City
Providence
State
RI
Country
United States
Zip Code
02903
Šrajer Gajdošik, Martina; Hixson, Douglas C; Brilliant, Kate E et al. (2018) Soft agar-based selection of spontaneously transformed rat prostate epithelial cells with highly tumorigenic characteristics. Exp Mol Pathol 105:89-97
Lopez, Chelsea E; Sheehan, Hannah C; Vierra, David A et al. (2017) Proteomic responses to elevated ocean temperature in ovaries of the ascidian Ciona intestinalis. Biol Open 6:943-955
Francois-Vaughan, Heather; Adebayo, Adeola O; Brilliant, Kate E et al. (2016) Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma. Carcinogenesis 37:408-419
Li, Ming; Tucker, Lynne D; Asara, John M et al. (2016) Stem-loop binding protein is a multifaceted cellular regulator of HIV-1 replication. J Clin Invest 126:3117-29
Breen, Lucas D; Pu?i?-Bakovi?, Maja; Vu?kovi?, Frano et al. (2016) IgG and IgM glycosylation patterns in patients undergoing image-guided tumor ablation. Biochim Biophys Acta 1860:1786-94
Mulvey, Hillary E; Chang, Audrey; Adler, Jason et al. (2015) Extracellular vesicle-mediated phenotype switching in malignant and non-malignant colon cells. BMC Cancer 15:571
Cheng, Yan; Holloway, Michael P; Nguyen, Kevin et al. (2014) XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther 13:675-86
Yousuf, Saad; Duan, MeiLi; Moen, Erika L et al. (2014) Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer. PLoS One 9:e92478
Cao, Weibiao; Tian, Wei; Hong, Jie et al. (2013) Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Physiol Gastrointest Liver Physiol 304:G322-7
Panagopoulos, Kiriaki; Cross-Knorr, Sam; Dillard, Christen et al. (2013) Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure. Mol Cancer 12:118

Showing the most recent 10 out of 127 publications